Nonoperating Income (Expense) in USD of OCULAR THERAPEUTIX, INC from 2012 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
Summary
OCULAR THERAPEUTIX, INC quarterly/annual Nonoperating Income (Expense) history and change rate from 2012 to Q3 2025.
  • OCULAR THERAPEUTIX, INC Nonoperating Income (Expense) for the quarter ending 30 Sep 2025 was -$720K, a 108% decline year-over-year.
  • OCULAR THERAPEUTIX, INC Nonoperating Income (Expense) for the twelve months ending 30 Sep 2025 was $1.16M.
  • OCULAR THERAPEUTIX, INC annual Nonoperating Income (Expense) for 2024 was -$21.7M, a 1420% decline from 2023.
  • OCULAR THERAPEUTIX, INC annual Nonoperating Income (Expense) for 2023 was $1.65M, a 78.4% decline from 2022.
  • OCULAR THERAPEUTIX, INC annual Nonoperating Income (Expense) for 2022 was $7.62M, a 89.3% decline from 2021.
Nonoperating Income (Expense), Trailing 12 Months (USD)
Nonoperating Income (Expense), Quarterly (USD)
Nonoperating Income (Expense), YoY Quarterly Change (%)
Nonoperating Income (Expense), Annual (USD)
Nonoperating Income (Expense), YoY Annual Change (%)

OCULAR THERAPEUTIX, INC Quarterly Nonoperating Income (Expense) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 $1.16M -$720K -$10.2M -108% 01 Jul 2025 30 Sep 2025 10-Q 04 Nov 2025
Q2 2025 $11.4M -$173K +$14K +7.49% 01 Apr 2025 30 Jun 2025 10-Q 05 Aug 2025
Q1 2025 $11.4M -$136K +$33.1M +99.6% 01 Jan 2025 31 Mar 2025 10-Q 05 May 2025
Q4 2024 -$21.7M $2.19M +$11.4M 01 Oct 2024 31 Dec 2024 10-K 03 Mar 2025
Q3 2024 -$33.1M $9.51M -$9.19M -49.2% 01 Jul 2024 30 Sep 2024 10-Q 04 Nov 2025
Q2 2024 -$23.9M -$187K -$75K -67% 01 Apr 2024 30 Jun 2024 10-Q 05 Aug 2025
Q1 2024 -$23.8M -$33.2M -$25.5M -328% 01 Jan 2024 31 Mar 2024 10-Q 05 May 2025
Q4 2023 $1.65M -$9.17M -$13M -340% 01 Oct 2023 31 Dec 2023 10-K 03 Mar 2025
Q3 2023 $14.6M $18.7M +$21.3M 01 Jul 2023 30 Sep 2023 10-Q 14 Nov 2024
Q2 2023 -$6.71M -$112K -$1.26M -110% 01 Apr 2023 30 Jun 2023 10-Q 07 Aug 2024
Q1 2023 -$5.44M -$7.77M -$13.1M -247% 01 Jan 2023 31 Mar 2023 10-Q 07 May 2024
Q4 2022 $7.62M $3.82M -$10.4M -73.1% 01 Oct 2022 31 Dec 2022 10-K 03 Mar 2025
Q3 2022 $18M -$2.64M -$24.8M -112% 01 Jul 2022 30 Sep 2022 10-Q 07 Nov 2023
Q2 2022 $42.8M $1.15M -$10.6M -90.2% 01 Apr 2022 30 Jun 2022 10-Q 07 Aug 2023
Q1 2022 $53.4M $5.29M -$18.1M -77.3% 01 Jan 2022 31 Mar 2022 10-Q 08 May 2023
Q4 2021 $71.5M $14.2M +$85.5M 01 Oct 2021 31 Dec 2021 10-K 11 Mar 2024
Q3 2021 -$14M $22.2M +$20.1M +976% 01 Jul 2021 30 Sep 2021 10-Q 07 Nov 2022
Q2 2021 -$34.1M $11.8M +$30.4M 01 Apr 2021 30 Jun 2021 10-Q 08 Aug 2022
Q1 2021 -$64.5M $23.3M +$28.2M 01 Jan 2021 31 Mar 2021 10-Q 09 May 2022
Q4 2020 -$92.8M -$71.3M -$66.7M -1444% 01 Oct 2020 31 Dec 2020 10-K 06 Mar 2023
Q3 2020 -$26.1M $2.06M -$2.3M -52.8% 01 Jul 2020 30 Sep 2020 10-Q 08 Nov 2021
Q2 2020 -$23.8M -$18.7M -$15.8M -555% 01 Apr 2020 30 Jun 2020 10-Q 09 Aug 2021
Q1 2020 -$8M -$4.9M -$7.43M -293% 01 Jan 2020 31 Mar 2020 10-Q 05 May 2021
Q4 2019 -$570K -$4.62M -$4.5M -3879% 01 Oct 2019 31 Dec 2019 10-K 28 Feb 2022
Q3 2019 $3.93M $4.37M +$4.56M 01 Jul 2019 30 Sep 2019 10-Q 05 Nov 2020
Q2 2019 -$630K -$2.85M -$2.61M -1089% 01 Apr 2019 30 Jun 2019 10-Q 07 Aug 2020
Q1 2019 $1.98M $2.53M +$2.84M 01 Jan 2019 31 Mar 2019 10-Q 08 May 2020
Q4 2018 -$860K -$116K +$270K +69.9% 01 Oct 2018 31 Dec 2018 10-K 12 Mar 2020
Q3 2018 -$1.13M -$194K +$177K +47.7% 01 Jul 2018 30 Sep 2018 10-Q 12 Nov 2019
Q2 2018 -$1.31M -$240K +$115K +32.4% 01 Apr 2018 30 Jun 2018 10-Q 07 Aug 2019
Q1 2018 -$1.42M -$310K +$41K +11.7% 01 Jan 2018 31 Mar 2018 10-Q 10 May 2019
Q4 2017 -$1.46M -$386K -$36K -10.3% 01 Oct 2017 31 Dec 2017 10-K 12 Mar 2020
Q3 2017 -$1.43M -$371K -$13K -3.63% 01 Jul 2017 30 Sep 2017 10-Q 07 Nov 2018
Q2 2017 -$1.41M -$355K -$17K -5.03% 01 Apr 2017 30 Jun 2017 10-Q 07 Aug 2018
Q1 2017 -$1.4M -$351K -$20K -6.04% 01 Jan 2017 31 Mar 2017 10-Q 08 May 2018
Q4 2016 -$1.38M -$350K +$12K +3.32% 01 Oct 2016 31 Dec 2016 10-K 07 Mar 2019
Q3 2016 -$1.39M -$358K -$8K -2.29% 01 Jul 2016 30 Sep 2016 10-Q 07 Nov 2017
Q2 2016 -$1.38M -$338K +$36K +9.63% 01 Apr 2016 30 Jun 2016 10-Q 08 Aug 2017
Q1 2016 -$1.42M -$331K +$134K +28.8% 01 Jan 2016 31 Mar 2016 10-Q 05 May 2017
Q4 2015 -$1.55M -$362K +$45K +11.1% 01 Oct 2015 31 Dec 2015 10-K 08 Mar 2018
Q3 2015 -$1.6M -$350K +$168K +32.4% 01 Jul 2015 30 Sep 2015 10-Q 09 Nov 2016
Q2 2015 -$1.76M -$374K +$72K +16.1% 01 Apr 2015 30 Jun 2015 10-Q 09 Aug 2016
Q1 2015 -$1.84M -$465K -$282K -154% 01 Jan 2015 31 Mar 2015 10-Q 10 May 2016
Q4 2014 -$1.55M -$407K 01 Oct 2014 31 Dec 2014 10-K 10 Mar 2017
Q3 2014 -$518K -$431K -495% 01 Jul 2014 30 Sep 2014 10-Q 10 Nov 2015
Q2 2014 -$446K -$345K -342% 01 Apr 2014 30 Jun 2014 10-Q 10 Aug 2015
Q1 2014 -$183K 01 Jan 2014 31 Mar 2014 10-Q 15 May 2015
Q3 2013 -$87K 01 Jul 2013 30 Sep 2013 10-Q 12 Nov 2014
Q2 2013 -$101K 01 Apr 2013 30 Jun 2013 10-Q 29 Aug 2014

OCULAR THERAPEUTIX, INC Annual Nonoperating Income (Expense) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$21.7M -$23.4M -1420% 01 Jan 2024 31 Dec 2024 10-K 03 Mar 2025
2023 $1.65M -$5.97M -78.4% 01 Jan 2023 31 Dec 2023 10-K 03 Mar 2025
2022 $7.62M -$63.9M -89.3% 01 Jan 2022 31 Dec 2022 10-K 03 Mar 2025
2021 $71.5M +$164M 01 Jan 2021 31 Dec 2021 10-K 11 Mar 2024
2020 -$92.8M -$92.2M -16179% 01 Jan 2020 31 Dec 2020 10-K 06 Mar 2023
2019 -$570K +$290K +33.7% 01 Jan 2019 31 Dec 2019 10-K 28 Feb 2022
2018 -$860K +$603K +41.2% 01 Jan 2018 31 Dec 2018 10-K 12 Mar 2020
2017 -$1.46M -$86K -6.25% 01 Jan 2017 31 Dec 2017 10-K 12 Mar 2020
2016 -$1.38M +$174K +11.2% 01 Jan 2016 31 Dec 2016 10-K 07 Mar 2019
2015 -$1.55M +$3K +0.19% 01 Jan 2015 31 Dec 2015 10-K 08 Mar 2018
2014 -$1.55M -$1.14M -275% 01 Jan 2014 31 Dec 2014 10-K 10 Mar 2017
2013 -$414K +$8K +1.9% 01 Jan 2013 31 Dec 2013 10-K 10 Mar 2016
2012 -$422K 01 Jan 2012 31 Dec 2012 10-K 20 Mar 2015
* An asterisk sign (*) next to the value indicates that the value is likely invalid.